Key Points
- EVP Craig Hopkinson sold 4,000 shares at an average price of $29.30 for a total of $117,200, reducing his stake by 5.74% to 65,740 shares valued at about $1.93M.
- Alkermes beat quarterly expectations with $0.49 EPS (vs. $0.41 estimate) and $394.19M revenue, and issued FY2025 guidance of 1.360–1.470 EPS.
- Wall Street sentiment is positive with a consensus rating of Moderate Buy and a $44.69 target, while institutional investors hold roughly 95.21% of the stock.
Alkermes plc (NASDAQ:ALKS - Get Free Report) EVP Craig Hopkinson sold 4,000 shares of Alkermes stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $29.30, for a total value of $117,200.00. Following the completion of the transaction, the executive vice president directly owned 65,740 shares in the company, valued at $1,926,182. This represents a 5.74% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Alkermes Stock Performance
NASDAQ ALKS opened at $28.90 on Tuesday. Alkermes plc has a one year low of $25.17 and a one year high of $36.45. The company's 50 day moving average price is $30.32 and its 200 day moving average price is $29.40. The firm has a market capitalization of $4.77 billion, a price-to-earnings ratio of 14.31, a PEG ratio of 1.70 and a beta of 0.53.
Alkermes (NASDAQ:ALKS - Get Free Report) last issued its earnings results on Tuesday, October 28th. The company reported $0.49 EPS for the quarter, beating analysts' consensus estimates of $0.41 by $0.08. Alkermes had a net margin of 22.27% and a return on equity of 21.81%. The business had revenue of $394.19 million for the quarter, compared to the consensus estimate of $355.23 million. During the same quarter last year, the firm posted $0.73 EPS. The business's revenue for the quarter was up 4.3% compared to the same quarter last year. Alkermes has set its FY 2025 guidance at 1.360-1.470 EPS. Sell-side analysts forecast that Alkermes plc will post 1.31 EPS for the current fiscal year.
Institutional Investors Weigh In On Alkermes
Large investors have recently added to or reduced their stakes in the stock. State Street Corp boosted its stake in Alkermes by 2.3% during the 2nd quarter. State Street Corp now owns 8,208,256 shares of the company's stock valued at $234,838,000 after purchasing an additional 185,586 shares during the period. Baker BROS. Advisors LP boosted its position in shares of Alkermes by 26.2% during the third quarter. Baker BROS. Advisors LP now owns 8,091,351 shares of the company's stock worth $242,741,000 after buying an additional 1,680,748 shares during the period. JPMorgan Chase & Co. grew its holdings in Alkermes by 488.6% in the 1st quarter. JPMorgan Chase & Co. now owns 5,234,995 shares of the company's stock worth $172,860,000 after buying an additional 4,345,523 shares in the last quarter. American Century Companies Inc. grew its stake in shares of Alkermes by 20.2% in the third quarter. American Century Companies Inc. now owns 4,397,471 shares of the company's stock worth $131,924,000 after purchasing an additional 740,248 shares in the last quarter. Finally, Geode Capital Management LLC increased its holdings in shares of Alkermes by 2.1% during the second quarter. Geode Capital Management LLC now owns 4,023,552 shares of the company's stock valued at $115,128,000 after purchasing an additional 83,858 shares during the period. 95.21% of the stock is owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
Several equities research analysts recently commented on the company. Truist Financial raised their target price on Alkermes from $50.00 to $55.00 and gave the company a "buy" rating in a report on Monday, November 17th. Piper Sandler reiterated an "overweight" rating and issued a $45.00 price objective (up previously from $38.00) on shares of Alkermes in a report on Thursday, October 23rd. Weiss Ratings reiterated a "hold (c+)" rating on shares of Alkermes in a research note on Tuesday, October 14th. Mizuho upped their target price on Alkermes from $40.00 to $45.00 and gave the company an "outperform" rating in a research report on Monday, October 27th. Finally, Royal Bank Of Canada boosted their target price on shares of Alkermes from $45.00 to $47.00 and gave the stock an "outperform" rating in a research report on Wednesday, October 22nd. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, Alkermes presently has a consensus rating of "Moderate Buy" and a consensus target price of $44.69.
Get Our Latest Research Report on Alkermes
About Alkermes
(
Get Free Report)
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
